ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-09 EDT			5-day change	1st Jan Change
8.06 ^USD	+1.77%		-10.14%	+60.56%

05-07	ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	MT
05-07	ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	CI

ImmunityBio : Investor Live Audio Webcast – ANKTIVA Post Approval

April 27, 2024 at 01:05 pm

Investor Live Audio Webcast - ANKTIVA Post Approval

Listen to Webcast

Attachments

Original Link
Permalink

Disclaimer

Immunitybio Inc. published this content on 26 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 April 2024 17:04:01 UTC.

Latest news about ImmunityBio, Inc.

ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	05-07	MT
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	05-07	CI
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	05-06	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline	05-03	MT
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types	05-02	CI
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline	04-30	MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating	04-29	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance	04-29	MT
Transcript : ImmunityBio, Inc. - Special Call	04-26
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer	04-25	CI
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer	04-23	MT
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	04-23	MT
Top Premarket Gainers	04-23	MT
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva	04-23	DJ
US FDA approves ImmunityBio's bladder cancer therapy	04-22	RE
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	04-22	CI
U.S. FDA approves ImmunityBio's bladder cancer therapy	04-22	RE
ImmunityBio Files Mixed Shelf	04-17	MT
North American Morning Briefing : Markets Steady -2-	03-26	DJ
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating	03-25	MT
ImmunityBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
North American Morning Briefing : Stock Futures -2-	03-19	DJ
ImmunityBio Announces Data from A Phase 1 Pilot Study	03-05	CI
ImmunityBio Says Cancer Vaccine Trial Moving to Controlled Phase	02-21	MT
ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	02-21	CI

Chart ImmunityBio, Inc.

Duration

Period

More charts

Company Profile

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - American Society of Clinical Oncology Annual Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ImmunityBio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.92 USD

Average target price

7.5 USD

Spread / Average Target

-5.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNITYBIO, INC.	+60.56%	5.36B
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-12.77%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-37.64%	17.45B
BEIGENE, LTD.	-6.50%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.53B

Bio Therapeutic Drugs